Elvina Almuradova/LinkedIn
Feb 5, 2025, 00:00
Elvina Almuradova: PTC significantly prolongs OS in patients with HER2+ metastatic breast cancer
Elvina Almuradova, Oncology Unit Lead at Can Hospitals Turkey, shared a post on LinkedIn about a recent paper by Yutaka Yamamoto et al. published in Journal of Clinical Oncology:
“PRECIOUS Study: Pertuzumab Retreatment Improves Overall Survival in HER2+ Metastatic Breast Cancer.
New findings from the PRECIOUS trial reveal that pertuzumab + trastuzumab + chemotherapy (PTC) significantly prolongs overall survival (OS) in patients with HER2-positive metastatic breast cancer (mBC) who were previously treated with pertuzumab-containing regimens.
Key Results:
- Overall Survival (OS): 36.2 months (PTC) vs. 26.5 months (TC)
- Progression-Free Survival (PFS, investigator-assessed): 5.5 months (PTC) vs. 4.2 months (TC)
Dual HER2 blockade with pertuzumab + trastuzumab may provide a survival benefit even after prior pertuzumab treatment.”
Authors: Yutaka Yamamoto et al.
More posts featuring Elvina Almuradova.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 4, 2025, 23:57
Feb 4, 2025, 23:30
Feb 4, 2025, 23:29
Feb 4, 2025, 22:36
Feb 4, 2025, 22:33
Feb 4, 2025, 22:31
Feb 4, 2025, 21:34
Feb 4, 2025, 21:28
Feb 4, 2025, 21:26